Evaluation of the Combined Treatment Approach “Robin” (Standardized Manual and Smartphone App) for Adolescents at Clinical High Risk for Psychosis

Nina Traber-Walker1,2*, Miriam Gerstenberg1,2, Sibylle Metzler1,2, Maria Raquel Joris1, Markus Karr1, Nadja Studer1, Marina Zulauf Logoz1, Alexander Roth1, Wulf Rössler2,3,4,5, Susanne Walitza1,2,6,7 and Maurizia Franscini1,2*

1 Department of Child and Adolescent Psychiatry and Psychotherapy, University Hospital of Psychiatry, University of Zurich, Zurich, Switzerland, 2 The Zurich Program for Sustainable Development of Mental Health Services (ZInEP), University Hospital of Psychiatry Zurich, Zurich, Switzerland, 3 Department of Psychiatry, Psychotherapy and Psychosomatics, Zürich University Hospital of Psychiatry, Zurich, Switzerland, 4 Department of Psychiatry and Psychotherapy, Charité University Medicine, Berlin, Germany, 5 Laboratory of Neuroscience, LIM27, Institute of Psychiatry, University of Sao Paulo, São Paulo, Brazil, 6 Neuroscience Center Zurich, University of Zurich and ETH Zurich, Zurich, Switzerland, 7 Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland

Introduction: The prevention of schizophrenia and other psychotic disorders has led researchers to focus on early identification of individuals at clinical high risk (CHR) for psychosis and to treat the at-risk symptoms in the pre-psychotic period. Although at-risk symptoms such as attenuated hallucinations or delusions are common in adolescents and associated with a marked reduction in global functioning, the evidence base of effective interventions for adolescents at CHR state and even first-episode psychosis is limited. Thus, the present protocol describes a study design that combines therapy modules for CHR adolescents with a smartphone application supporting the young individuals between the therapy sessions. The treatment approach “Robin” is based on existing therapy strategies for adolescents with first episode of psychosis and the available recommendations for adults with at-risk symptoms.

Methods: The evaluation aims firstly to compare the efficacy of Robin in 30 CHR adolescents aged 14–18 to an active control group (treatment as usual) from a previous study. Primary outcome measures will be at-risk symptomatology, comorbid diagnosis, functioning, self-efficacy, and quality of life. For the prospective intervention condition (16 weekly individual sessions + a minimum 4 family sessions), help-seeking adolescents with CHR for psychosis, aged 14–18, will be recruited over 3 years. At-risk and comorbid symptoms, functioning, self-efficacy, and quality of life are monitored at six time points (baseline, during the treatment period; immediately after intervention; and 6, 12, and 24 months later) and compared with the respective measures of the active control group.

Discussion: To the best of our knowledge, this is the first controlled trial to test the efficacy of a specific early psychosis treatment in combination with a smartphone application for adolescents at CHR for developing psychosis. The results of the study are expected...
to add information that may substantially decrease the burden of CHR adolescents and increase their resilience. It may offer age-adapted and targeted strategies to guide clinicians in the treatment of these vulnerable individuals. Furthermore, research in the field of early intervention will be enriched by our findings.

**Clinical Trial Registration:** www.ClinicalTrials.gov, identifier NCT03829527.

**Keywords:** psychosis, eMental health, psychological intervention, youth mental health, clinical high risk of psychosis, early intervention

**INTRODUCTION**

Psychotic disorders are severe mental illnesses that typically emerge in late adolescence or early adulthood (1). The disorders lead to considerable social and economic deficits, as well as burden for the individual and family (2). Prior to the onset of the first psychotic episode, the majority of the individuals experience attenuated psychotic symptoms, known as at-risk symptoms (3).

Two different sets of clinical high risk (CHR) criteria have been developed for the purpose of early identification of individuals at CHR: 1) the basic symptom criteria focusing on subtle, subjectively experienced changes in cognition and perception and 2) the ultra-high-risk criteria, such as attenuated positive symptoms indicating the imminent manifestation of psychosis (4). In the present article, we use the term CHR state, which includes both of these current risk concepts.

There is an ongoing discussion as to whether or not to treat at-risk symptoms (5–7). The rates of CHR individuals transitioning to psychotic disorders have declined over the years of early detection research (8), and the specificity of at-risk symptoms is questioned (5, 9). At-risk symptoms are common in the general population, particularly during adolescence; it is a clinical challenge as to how to differentiate between young people who are at risk and those who are not (10, 11). Nevertheless, leading experts in the field of early intervention in psychosis have claimed that treatment of at-risk symptoms in the help-seeking population is justified independently of the risk of conversion to psychosis [for example, Refs. (12–15)].

CHR individuals and their caregivers report high levels of distress due to these symptoms (16). The CHR state is associated with suicidality, impairments to global functioning, and a decline in quality of life (17–23). CHR individuals report poorer social relationships and higher rates of loneliness than do healthy peers (24). Furthermore, CHR individuals seem to have poor coping skills, low levels of self-efficacy, and negative metacognitive belief similar to that seen in patients with depression or with a frank psychosis (25–27). Recent studies have shown a high prevalence of psychiatric comorbidities in CHR populations for psychosis (28, 29), especially in younger CHR individuals (20). Moreover, the CHR state is associated with long-term implications, independent of conversion to psychosis. A recent study showed that about half of non-transitioned CHR individuals remained functionally impaired and presented with at least one comorbid disorder at a 6-year follow-up (30). On the other hand, CHR individuals who convert to psychosis have shown poorer clinical outcomes than do first episode psychosis patients without a history of at-risk symptoms (31). Consequently, current data clearly favor targeting and treating at-risk symptoms in help-seeking individuals.

Although at-risk symptoms are common in adolescents and associated with a marked reduction in functioning in this age group (23), the evidence base required to guide effective interventions for CHR adolescents and even first-episode psychosis is limited (15, 32–35). Most intervention studies in the CHR population have included adult patients, with only a few including younger patients (36–40). A majority of them used the same treatment approaches for adults and adolescents. Consequently, there is a lack of investigation targeting age-appropriate treatment strategies in this vulnerable age group. The transition from childhood to adulthood is a very complex developmental stage, and age-adapted intervention strategies are required. The CHR state can disrupt social and psychological development, such as the achievement of educational goals or the construction of peer relationships. Therefore, minor CHR individuals need treatment strategies that address the complex symptomatology, the associated burden, and their reduced functioning. Furthermore, when focusing on engagement in therapy during first psychotic episodes, the data demonstrated that age-appropriate treatment approaches drawing from youth specific interests are needed to address and involve the younger patients (32, 41).

To fill this gap, the experts from the specialized outpatient care unit for early intervention in psychosis at the Department of Child and Adolescent Psychiatry and Psychotherapy, Psychiatric University Hospital of the University of Zurich (CAPS), developed the specialized treatment approach "Robin" for CHR adolescents. The treatment program Robin is an integrated psychotherapeutic approach. Robin comprises individual therapy, family sessions, and a smartphone application for supporting patients between sessions. The therapy modules are based on treatment strategies in CHR adults (6, 14, 42–44) and recommendations for adolescents with first episodes of psychosis (33, 45, 46). It follows the guidance on early intervention in CHR states of psychosis of the European Psychiatric Association (EPA) (15).

The treatment modules are also based on existing concepts of cognitive behavioral therapy (CBT). CBT is currently the most widely approved psychological intervention in early intervention of psychosis and recommended by EPA guidance (15). Previous studies showed that CBT may prevent or at least postpone a first psychotic episode in CHR individuals (47);
however, these promising findings need replication, and studies applying CBT in adolescents are rare. Cognitive remediation is used as a supplement treatment and focuses on improving cognitive and social skills. Additionally, the treatment modules comprise aspects of systemic therapy, which have been found to be efficacious in the treatment of psychosis in adult patients (48). Assuming that family environment plays a more relevant role in adolescents than in adults, there is a strong rationale for the possible benefits of systemic intervention in adolescents with CHR state. The initial studies of systemic treatment approaches in adolescents with psychosis (32) and CHR adolescents are promising (36, 39).

In addition to the above, the intervention also includes the smartphone application “Robin Z,” Smartphones have become everyday devices, and most people use them in their daily routine. Previous analyses showed that for young people, in particular “digital natives,” it may be helpful to develop technology-based treatment approaches as a way of connecting with them about mental health issues (49–51). There is increasing interest in using mobile technologies such as smartphone applications in mental health care (52–54). Primarily, mobile technologies were utilized to collect research data. These technologies allow for real-time assessment. This provides more accurate data about real-world contexts in which experiences are made or behaviors occur (55, 56). So risk and protective factors in the psychosocial environment and their impact on mental health can be more easily identified. Further, studies with smartphone assessments showed higher engagement in completing all examinations and lower dropout rates than did studies with paper-and-pencil assessments (57, 58). Recently, research projects have examined feasibility and validity of mobile technologies in supporting therapy (53, 59). Smartphone interventions have many advantages like accessibility, portability, 24-h support, or real-time intervention. Using smartphones in everyday situations (i.e., on the bus, at school, and on the street) is routine, and so interventions via smartphone are not likely to be stigmatizing (49). The problem of recall bias in retrospective reports can be reduced or avoided. This helps the psychotherapist to give more tailored feedback to support and reinforce changes in the patients’ behavior according to their psychological health. Furthermore, self-monitoring also provides advantages for the patients themselves. The repeated measurement of their symptoms and mood can reveal insights into their psychological processes (60). Reid and colleagues (61) found an increased self-awareness regarding their symptoms and mood after using a symptom-monitoring smartphone application in a group of younger psychiatric patients. There is also evidence that medication adherence can be improved through smartphone intervention (62, 63).

In the treatment of psychotic disorders, the first research results from the use of smartphone applications are promising (62, 64–68); however, there is little known about mobile technologies addressing at-risk symptoms (50). Despite current analysis demonstrating young people would be interested in using mobile technologies, there is a lack of investigations with this population (49, 51). The available studies have shown a high acceptance and subjective satisfaction with mobile interventions in young people with psychiatric problems (57, 61, 69).

There is great heterogeneity across symptomatology and functioning in the CHR population (30, 70). As a consequence, individualized adaptive treatment approaches are required. While some individuals will respond to an intervention, others will not. Robin is an individually tailored approach, and the treatment is personalized to the individuals’ special needs depending on their stage of illness, presence of comorbidities, or functional impairment.

The current clinical trial “Evaluation of the Treatment program Robin” (ETRo) has two main study goals:

1. to investigate the feasibility and impact of the combined treatment program: the structured therapy and the smartphone application; and
2. to investigate the efficacy of this specific intervention versus treatment as usual (TAU).

Hypotheses of the study:

Hypothesis 1: Robin is feasible and accepted in this young population of CHR individuals. The adolescents will show high treatment engagement.

Hypothesis 2: Robin improves the quality of life and self-efficacy at 6-, 12-, and 24-month follow-up in individuals with CHR compared with individuals with CHR who received TAU.

Hypothesis 3: Robin enhances the rate of adolescents with clinical and psychosocial functional remission at 6-, 12-, and 24-month follow-up than does TAU.

METHODS AND STUDY DESIGN

The ETRo Trial is a prospective, single-center, follow-up study comparing a specific treatment program for adolescents with at-risk symptoms with a sample from a previous study having received TAU.

Participants

Participant recruitment will run between September 2017 and continue until September 2020 in the early recognition center for psychosis of the Department of Child and Adolescent Psychiatry and Psychotherapy, Psychiatric University Hospital of the University of Zurich (CAPS). The ETRo trial is a naturalistic treatment study. All participants will be help-seeking adolescents (aged 14–18) with at-risk symptoms assessed at the early recognition center. The purpose of the study, the study process, risks, benefits, and alternatives will be explained to all participants and their caregivers according to ethical principles. All participants will be asked to give a written informed consent in accordance with the national law. For inclusion, participants must meet at least one of the following at-risk criteria: 1) at least two self-experienced and self-reported cognitive basic symptoms as assessed by the Schizophrenia Proneness Interview Child and Youth Version (SPI-CY) (71) and/or 2) at least one attenuated psychotic symptom for psychosis assessed by the Structured Interview for Prodromal Syndromes (SIPS) (72).
Exclusion criteria for study participation include a diagnosis of a psychotic disorder, current substance or alcohol dependence, aged below 14, insufficient German or English language ability, or low intellectual abilities with IQ < 75.

**Study Design**
Within this prospective evaluation data for at-risk symptoms and comorbid symptoms, global functioning, self-efficacy, and quality of life will be collected at six time points (baseline, during the treatment period; immediately after intervention; and 6, 12, and 24 months later). The treatment period will be 16 weekly, individual sessions combined with at least four family sessions starting after the baseline clinical assessment (Figure 1).

**Study Intervention**
The integrated psychotherapeutic treatment approach Robin combines standardized treatment modules with a smartphone application. The treatment is targeted at at-risk symptoms as well as comorbid disorders. Improving quality of life and daily functioning is also a primary target in therapy and outcome measures. An important part of the program is the work on the individuals’ self-esteem and their experience of self-efficacy. The program is solution and resource oriented in reframing one's symptoms. A variety of questioning techniques are used to enrich the individuals’ perspectives, to identify problems, and to create more possibilities in dealing with daily difficulties. Weekly homework tasks are usually given to transfer the insights and experiences from the therapy in the individuals' daily life.

The first session is a family session directly after the clinical baseline assessment. In this session, there is a detailed psychoeducation to develop a concept of the CHR state with the adolescent and their caregivers. The therapeutic goals will be declared. The therapeutic modules provide information and individual approaches to target specific complaints of the adolescent within the following 15 sessions. The individuals are asked to make a daily record of their symptoms, mood, sleeping patterns, and alcohol and drug use over the entire treatment period. The records are discussed every week in the first part of the therapy session.

The psychotherapists consist of two female graduated psychologists, NT-W and SM, trained in research early recognition programs and experienced in treatment of clinical outpatients. MF, medical doctor, head of the early recognition program.

**FIGURE 1** Flow chart of the assessments from baseline to 24 months of follow-up.
service for adolescents, and the respective psychologist will conduct the family sessions together.

In accordance with the EPA guidance (15), low-dose second-generation antipsychotics are used when at-risk symptoms are severe and progressive with only minimal or clearly declining insight. The medication is monitored and supervised by M. F.

App Robin Z
The app Robin Z (Figure 2) was developed to enrich the treatment sessions. A modular version of the app was developed and modified after the first pilot investigations with patients (N = 7, aged 14–18) and clinicians from the CAPS (N = 10). All clinicians within the pilot study reported that they would like to use the app Robin Z to enrich their therapeutic approaches. All patients in the pilot project used the app in their daily lives. Modules containing information about symptoms and coping strategies were used most frequently by patients. The findings were used to improve and adapt the application. In September 2017, the development of Robin Z was finalized and published on iTunes and Google Play. The technical aspects of Robin Z are regularly maintained without changes to the content.

The app is developed as an adjunct to the therapy and not a replacement for appropriate medical treatment and management. It is not at treatment itself, and it is not seen as a medical product according to the Swiss Medical Devices Ordinance Act. The authors recommend using the app in combination with a psychological treatment. Furthermore, it may be used after completion of the study and/or therapy.

The app works offline and is not connected to the internet. Data collected by the app are stored in a private directory. These data are protected by the operating system and are inaccessible to other software on the device. The app does not transfer or store any data on the internet, and no data are stored outside of its private directory. In addition, the app is also password protected.

The app contains the following features:

Symptom management: Users will receive information about their symptoms and suggestions for managing them via the app. In therapy, these coping strategies are discussed with the patient and, if necessary, explained by the clinician. The adolescents can also define their own coping strategies and note helpful thoughts under the function “Memo.” The adolescents will be asked about their symptoms and their mood several times a day. They agree together with their therapists how many prompts they will receive each day. The symptom records are saved under a “Logbook.”

Medication: The individuals can record their medication, and they can set up a reminder. Medication adherence can be monitored through the Logbook.

Crisis intervention: In collaboration with their therapists, adolescents can set up a crisis intervention plan including emergency contacts. They can call the emergency contact directly via the app.

Weekly goals: The individuals can set their own goals. This means small, attainable goals so that they experience success. Furthermore, they are supported when dealing with their daily challenges. The goals are decided in the therapy session.

Library: The “Library” offers positive reinforcement for dealing with daily life. It consists of a list of strengths and positive experiences.

The lists of strengths and positive experiences are discussed and extended on every week in therapy. There are suggestions for positive activities that the adolescents can engage in daily. The individuals are encouraged to do at least one positive activity per day. The suggestions are split into the following categories:

- Reward
- Creative activities
- Movement
- Social interaction
- Cognitive training
- Wellness
- Relaxation exercises

Standard Care
The control condition is composed of a control group from a former early recognition study in Zurich (ZInEP) [e.g., Ref. (73)]. The control group consists of 62 adolescents meeting CHR criteria (25 female, age range 13–18 years, mean age 15.06) who historically signed a declaration of consent regarding the use of their data. The sample was accrued from April 2010 to July 2012. The individuals of this subsample of the ZInEP had been treated with non-standardized psychological intervention (TAU) also at the CAPS. Within the ZInEP study, the comparable primary and secondary outcomes (at-risk symptoms, comorbid symptoms, global functioning, self-efficacy, and quality of life) have been evaluated at the same time points (at baseline and 6, 12, 24, and 36 months later). Since we expect a high interindividual variability of symptom fluctuation, reduction, or progression during the phase of intervention, we plan to reduce further putative impact of sex and age and to match individuals from the intervention group to ZInEP individuals accordingly. Consequently, 30 individuals from the ZInEP sample will be included in the statistical analysis.

Primary Outcome
Primary outcome measures are transition to psychotic disorders, changes in at-risk as well as comorbid symptomatology, global functioning, life quality, and self-efficacy. All these measures will be compared with those of the control group.

Secondary Outcome
Secondary outcome measures are the feasibility, user-friendliness, and acceptance of the treatment program Robin and the smartphone application Robin Z. Therefore, discontinuation of the therapy and subjective satisfaction with the therapy will be assessed. Furthermore, data about hospitalization, suicidality, and medication adherence will be collected and analyzed in comparison with those of the control group.

Assessment
At baseline, demographic variables, past psychiatric illness, and treatment information are obtained from the participants and their caregivers. Before participating in the study, all patients will
undergo a clinical assessment and diagnostic process according to *International Classification of Diseases*, Tenth Revision, criteria. Adolescents will be asked to complete a questionnaire about their personality traits PSSI (74) and to perform the Wechsler Intelligence Scale for Children (75) or Wechsler Adult Intelligence Scale for individuals aged > 16 years 11 months (76) to evaluate their cognitive profile.

In accordance with EPA guidance on the early detection of CHR states of psychoses, the CHR status is assessed with the Schizophrenia Proneness Interview Child and Youth Version (71) and the Structured Interview for Prodromal Syndromes (72). All investigators are either psychologists or psychiatrists. They are trained to a “gold standard,” and reliability will be measured for the duration of the trial. Comorbid mental disorders will be screened for with the Mini-International Neuropsychiatric Interview for Children and Adolescents based on *Diagnostic and Statistical Manual of Mental Disorders*, Fourth Edition (77). The severity of depression will be measured using the Hamilton Depression Scale (78).

Information about functioning will be measured with the Global Assessment of Functioning Scale (GAF) (79), Social and Occupational Functioning Assessment (SOFA) Scale (80), and Global Functioning: Social Scale (GF: Social) (81). Data about quality of life, personality traits, and self-efficacy will be collected using the Manchester Short Assessment of Quality of Life (MANSZA) (82) and the General Self-Efficacy Scale (SWE) (83).

Treatment satisfaction will be evaluated with the treatment evaluation questionnaire for adolescent patients FFB-J (84). A feedback form created specifically for the app will gather information regarding acceptance and contentment with the smartphone application Robin Z (Table 1).

**Statistical Analysis**
Statistical analysis will be reported in accordance with the Consolidated Standards of Reporting Trials statement.

**Clinical Analyses**
Differences in the primary and secondary outcomes between the two study groups at all time points will be examined with repeated measures analysis of variance and standardized effect sizes (Cohen's $d$) will be reported. Their respective confidence intervals will be calculated for comparison. Response and remission rates will be compared across groups with contingency tables and differences tested with $\chi^2$. All unidirectional hypotheses will be tested one sided; bidirectional hypotheses will be tested two sided. Alpha is set to $p < 0.05$. All analyses will be conducted within SPSS.

A linear mixed model approach will be used to assess differences in the primary and secondary outcomes between the two study groups. Logistic regression will be used to assess response and remission rates across the groups. Medication, education, and intelligence will be taken into account as confounding factors by including them in mixed model and logistic regression model, respectively. All unidirectional hypotheses will be tested one sided; bidirectional hypotheses will be tested two sided. Significance level $\alpha$ is set to 0.05.
Sample Size

The sample size calculation is based on testing differences between the TAU group and the intervention group. It has been assumed that the intervention group could achieve at least 10% additional improvement than the TAU group for the main instruments at the 6-month follow-up assessment (Table 2). Standard deviations for the different instruments have been estimated with data from adolescent participants of a previous early recognition study (73). Sample size calculation was assessed using SAS PROC Power, Version 9.4.

To the best of our knowledge, there is no comparable study reporting effect sizes of the improvement of clinical outcome variables such as overall symptom dimensions and functioning in CHR adolescents. Considering the respective outcome measures, the sample size ranges from 16 to 27 (Table 2). In a conservative approach, we chose to include 30 individuals per group.

Data Monitoring and Management

Study data will be entered onto a study specific database (Research Electronic Data Capture REDCap) following a standard operating procedure. All data will be collected on paper case report forms (CRFs) that are anonymized and stored at the CAPS. Data will be entered by researchers electronically into the REDCap database. A random subset of data will be checked for quality control by independently checking the paper CRFs, and electronically entered data and any errors will be corrected. Only the leading investigators, trial statistician, and researchers will have access to the final dataset.

Sample Size

The sample size calculation is based on testing differences between the TAU group and the intervention group. It has been assumed that the intervention group could achieve at least 10% additional improvement than the TAU group for the main instruments at the 6-month follow-up assessment (Table 2). Standard deviations for the different instruments have been estimated with data from adolescent participants of a previous early recognition study (73). Sample size calculation was assessed using SAS PROC Power, Version 9.4.

To the best of our knowledge, there is no comparable study reporting effect sizes of the improvement of clinical outcome variables such as overall symptom dimensions and functioning in CHR adolescents. Considering the respective outcome measures, the sample size ranges from 16 to 27 (Table 2). In a conservative approach, we chose to include 30 individuals per group.

Data Monitoring and Management

Study data will be entered onto a study specific database (Research Electronic Data Capture REDCap) following a standard operating procedure. All data will be collected on paper case report forms (CRFs) that are anonymized and stored at the CAPS. Data will be entered by researchers electronically into the REDCap database. A random subset of data will be checked for quality control by independently checking the paper CRFs, and electronically entered data and any errors will be corrected. Only the leading investigators, trial statistician, and researchers will have access to the final dataset.

### TABLE 1 | Description of assessments from baseline to endpoint of study.

| Time point (months) | Baseline | Intervention (16 session) | Follow-up |
|---------------------|----------|---------------------------|-----------|
| Socio-demographic characteristics | x        | x                         | x         |
| Clinical diagnosis according to ICD-10 | x        | x                         | x         |
| Re-evaluation of all diagnoses | x        | x                         | x         |
| Medication | x        | x                         | x         |
| Intellectual ability: | x        | x                         | x         |
| WISC/WAIS | x        | x                         | x         |
| Personality traits: | x        | x                         | x         |
| Clinical High Risk State: | x        | x                         | x         |
| SPI-CY | x        | x                         | x         |
| SIPS | x        | x                         | x         |
| Comorbidities: | x        | x                         | x         |
| MINI KID | x        | x                         | x         |
| Depression: | x        | x                         | x         |
| HAMD | x        | x                         | x         |
| Functioning: | x        | x                         | x         |
| GAF | x        | x                         | x         |
| GF; Social | x        | x                         | x         |
| SOFAS | x        | x                         | x         |
| Quality of Life: | x        | x                         | x         |
| MANSA | x        | x                         | x         |
| Self-efficacy: | x        | x                         | x         |
| SWE | x        | x                         | x         |
| Satisfaction with treatment: | x        | x                         | x         |
| FFE | x        | x                         | x         |

GAF, Global Assessment of Functioning Scale; GF, Social, Global Functioning; Social Scale; HAMD, Hamilton Depression Rating Scale; ICD-10, International Classification of Diseases, Tenth Revision; MANSA, Manchester Short Assessment of Quality of Life; SIPS, Structured Interview for Prodromal Syndromes; SOFAS, Social and Occupational Functioning Assessment Scale; SWE, General Self-Efficacy Scale; WAIS, Wechsler Adult Intelligence Scale; WISC, Wechsler Intelligence Scale for Children.

### TABLE 2 | Numbers needed to detect a significant difference between TAU and the intervention group for the different psychological instruments.

| Instrument | Assumed additional improvement in comparison with TAU (∑ Total points per scale) | Maximum (∑ Total points) | N per group |
|------------|--------------------------------------------------------------------------------|--------------------------|-------------|
| SIPS       | −15                                                                            | 114                      | 17          |
| SPI-CY     | −9                                                                             | 84                       | 16          |
| SWE        | +4                                                                             | 40                       | 27          |
| GAF        | +10                                                                            | 100                      | 24          |

GAF, Global Assessment of Functioning Scale; SIPS, Structured Interview for Prodromal Syndromes; SPI-CY, Schizophrenia Proneness Interview Child and Youth Version; SWE, General Self-Efficacy Scale; TAU, treatment as usual.
Serious adverse events are regularly monitored and documented by the research team and reported immediately to the chief investigator and/or a senior clinical member of the team.

Ethical Issues
This study is being conducted in accordance with globally accepted standards of good clinical practice, in agreement with the Declaration of Helsinki and with national regulations of the Swiss Ethics Committees on research involving humans. The local ethics committee in Zurich has approved the study procedure, study information, and informed consent forms in May 2017 before the inclusion of a first patient in the trial. The study has been registered at the international trial register ClinicalTrials.gov (ClinicalTrials.gov identifier NCT03829527) and the national trial register kofam (kofam.ch identifier SNCTP000003148).

Every participant can drop out of the study at any time. All dropouts will be documented in the CRFs. The study investigators ensure that all mental health professionals involved in the study are qualified and informed about the protocol, interventions, and trial-related duties.

DISCUSSION
Despite evidence suggesting that young individuals with at-risk symptoms may profit best from specialized treatment approaches (85), little is known about age-appropriate treatment strategies in this vulnerable age group (15). The treatment program Robin has been developed to fill this gap.

Our treatment approach Robin is an integrated approach based not only on CBT but also on systemic therapy. The treatment is both solution and resource focused. Furthermore, Robin is an individualized treatment approach in line with the individual needs of the particular patients, which should lead to a high acceptance. Furthermore, age-appropriate treatment material, including a smartphone app and the involvement of the family, may result in higher engagement in therapy (32, 41, 49). The smartphone application Robin Z has been developed to enrich the treatment and to increase treatment satisfaction through providing support between sessions. Previous studies have already demonstrated that mobile-based interventions are feasible and accepted by psychotic patients (49, 58, 59, 66); thus, we expect the same for CHR individuals.

In accordance with EPA guidance in early intervention in CHR states of psychoses (15), a primary aim of this treatment approach is to improve the daily functioning. Thus, the study group decided to primarily focus on quality of life, self-efficacy, and functioning. These areas have been shown to be most impacted in adolescents and often prompt them to seek help (18, 30, 44, 86, 87). In contrast, at-risk symptoms are not necessarily the cause of the highest psychological strain and burden for the patient. Furthermore, we expect a remission or at least a significant decline of the at-risk symptoms in most patients after the treatment period. Prior evidence has demonstrated that at-risk symptoms, especially in adolescents, show high levels of fluctuation (70, 88). How much this fluctuation symptoms or remission rates are associated with a specific intervention is currently unknown. Our first analysis of symptomatology in the control group also showed a high reduction of at-risk symptoms during follow-up compared with the baseline.

The integrated and age-adapted treatment approach as well as the focus on outcomes other than the putative progression of symptomatology and onset of psychosis also seems to be supported by a recent network meta-analysis. Davies et al. (89) compared efficacy of different preventive interventions in CHR individuals considering conversion rates in psychosis and acceptability of treatment intervention. The findings demonstrated a lack of evidence to favor a specific intervention to prevent onset of psychosis, and there were no significant differences in acceptability between the treatment approaches. In the context of non-superiority of any intervention, the authors questioned CBT as the most widely adopted intervention in the early intervention of psychosis.

Using a control group of our previous early recognition study ZInEP and a non-randomized design could be possible sources of bias. However, data of the control group participants of ZInEP were reassessed at the same time points (6, 12, and 24 months), and identical measures were used. The TAU was carried out in the same outpatient service under the supervision of M. F. There were no major changes in the Swiss health system between 2010 and 2018 that could have had an influence on the frequency or intensity of therapeutic sessions. The outpatient mental healthcare system in Zurich has remained widely unchanged since then. Another limitation of the control group may be the naturalistic setting. As their treatment was not standardized, many treatment variables, such as the treatment approach or the therapists themselves, cannot be controlled for. However, even though a moderate sample size may limit statistical controlling, important confounders such as effect of medication, hospitalization, and treatment frequency may be identified in both groups and controlled for. Our control group is an extensively and carefully assessed large sample of CHR adolescents (N = 62) in the same age range and from the same geographical area. The sample is double that of the intervention sample and allows for age and sex matching to individuals in the intervention study. Consequently, more resources can be allocated to recruiting the experimental group, and therefore, the chance of achieving a larger sample will be increased. This will also help to reduce ethical concerns, as the help-seeking patients will be reporting a high level of distress and requesting a specific treatment. The treatment is based on the current research results in the field of early intervention and prevention of psychosis, as well on the clinical expert knowledge from the therapists in the early intervention center. Therefore, our study team will act on the assumption that the treatment approach Robin will lead to the best possible outcome.

Another reason for utilizing a control group from a former study is the smartphone application Robin Z. Since the application can be downloaded for free from App Store and Google Play, it seems difficult to eliminate Robin Z as a confounder. Even if the therapists do not ask the control participants to download the application, their use of it cannot be ruled out. Although the usage of Robin Z alone will not replace treatment, the authors
assume that combination of psychological intervention and the use of the app will lead to a better psychological outcome.

To the authors' knowledge, this is the first controlled trial to test the efficacy of a specific treatment manual in combination with a smartphone application for adolescent patients at CHR. The results of the study are expected to add important knowledge within the research fields of prevention and early intervention in psychosis in adolescents within the peak age of psychosis onset.

**DISSEMINATION**

After study completion, the results of the primary and secondary analyses will be published in international peer-reviewed journals (at least one specialized in addiction and another in adolescent psychiatry).

**TRIAL STATUS**

The recruitment started in September 2017. Participants will be included till September 2020.

**REFERENCES**

1. Kessler RC, Amminger GP, Aguilar-Gaxiola S, Alonso J, Lee S, Ustün TR. Age of onset of mental disorders: a review of recent literature. *Curr Opin Psychiatry* (2007) 20:359–64. doi: 10.1097/YCO.0b013e32816eb8c
2. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jonsson B, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. *Eur Neuropsychopharmacol* (2011) 21(9):655–79. doi: 10.1016/j.eunetrev.2011.07.018
3. Fusar-Poli P, Borgwardt S, Bechdolf A, Addington J, Riecher-Rossler A, Schultz-Lutter F, et al. The psychosis high-risk state: a comprehensive state-of-the-art review. *Arch Gen Psychiatry* (2013) 70(1):107–20. doi: 10.1001/jamapsychiatry.2013.269
4. Schultz-Lutter F, Michel C, Schmidt SJ, Schimmelmann BG, Maric NP, Salokangas RKR, et al. EPA guidance on the early detection of clinical high risk states of psychoses. *Eur Psychiatry* (2015) 30(3):405–16. doi: 10.1016/j.eurpsy.2015.01.010
5. Fusar-Poli P, Cappucciati M, Rutigliano G, Schultz-Lutter F, Bonoldi I, Borgwardt S, et al. At risk or not at risk? A meta-analysis of the prognostic accuracy of psychometric interviews for psychosis prediction. *World Psychiatry* (2015) 14(3):322–32. doi: 10.1002/wps.20250
6. Fusar-Poli P, McGorry PD, Kane JM. Improving outcomes of first-episode psychosis: an overview. *World Psychiatry* (2017) 16(3):251–65. doi: 10.1002/wps.20446
7. Guloksuz S, van Os J. Need for evidence-based early intervention programmes: a public health perspective. *Evid Based Ment Health* (2018) 21(4):128–30. doi: 10.1136/ebmental-2018-300300
8. Hartmann JA, Yuen HP, McGorry PD, Yung AR, Lin A, Wood SJ, et al. Declining transition rates to psychotic disorder in "ultra-high risk" clients: investigation of a dilution effect. *Schizophr Res* (2016) 170(1):130–6. doi: 10.1016/j.schres.2015.11.026
9. Jones N, Shattell M, Kelly T, Brown R, Robinson LV, Renfro R, et al. "Did I push myself over the edge?": complications of agency in psychosis onset and development. *Psychosis* (2016) 8(4):324–35. doi: 10.1080/17522439.2016.1150501
10. Kelleher I, Cannon M. Psychotic-like experiences in the general population: characterizing a high-risk group for psychosis. *Psychol Med* (2011) 41(1):1–6. doi: 10.1017/S0033291710001005
11. Schultze-Lutter F, Michel C, Ruhrmann S, Schimmelmann BG. Prevalence and clinical relevance of interview-assessed psychosis-risk symptoms in the young adult community. *Psychol Med* (2018) 48(7):1167–78. doi: 10.1017/S0033291717002586
12. Bertolote J, McGorry P. Early intervention and recovery for young people with early psychosocial consensus statement. *Br J Psychiatry* (2005) 187(S48):116–9. doi: 10.1192/bjp.187.48.s116
13. Correll CU, Hauser M, Author AM, Cornblatt BA. Research in people with psychosis risk syndrome: a review of the current evidence and future directions. *J Child Psychol Psychiatry* (2010) 51(4):390–431. doi: 10.1111/j.1469-7610.2010.02235.x
14. Fusar-Poli P, Yung AR, McGorry P, Van Os J. Lessons learned from the psychosis high-risk state: towards a general staging model of prodromal intervention. *Psychol Med* (2014) 44(1):17–24. doi: 10.1017/S0033291713000184
15. Schmidt SJ, Schultze-Lutter F, Schimmelmann BG, Maric NP, Salokangas RKR, Riecher-Rossler A, et al. EPA guidance on the early intervention in clinical high risk states of psychoses. *Eur Psychiatry* (2015) 30(3):388–404. doi: 10.1016/j.eurpsy.2015.01.013
16. Kline E, Thompson E, Bussell K, Pitts SC, Reeves G, Schiffman J. Psychosis-like experiences and distress among adolescents using mental health services. *Schizophr Res* (2014) 152(2–3):498–502. doi: 10.1016/j.schres.2013.12.012
17. Cornblatt BA, Carrión RE, Addington J, Seidman L, Walker EF, Cannon TD, et al. Risk factors for psychosis: impaired social and role functioning. *Schizophr Bull* (2012) 38(6):1247–57. doi: 10.1093/schbul/bsr136
18. Cotter J, Bucci S, Drake RJ, Yung AR, Carney R, Edge D. Exploring functional impairment in young people at ultra-high risk for psychosis: a qualitative study. *Early Interv Psychiatry* (2018) 1–9. doi: 10.1111/eip.12560
19. Fusar-Poli P, Rocchetti M, Sadrella A, Avila A, Brandizzi M, Caverzasi E, et al. Disorder, not just state of risk: meta-analysis of functioning and quality of life in people at high risk of psychosis. *Br J Psychiatry* (2015) 207(3):198–206. doi: 10.1192/bjp.bp.114.157115
20. Gerstenberg M, Theodoridou A, Traber-Walker N, Franscini M, Wotruba D, Metzler S, et al. Adolescents and adults at clinical high-risk for psychosis: age-related differences in attenuated positive symptoms syndrome prevalence and entanglement with basic symptoms. *Psychol Med* (2016) 46(5):1069–78. doi: 10.1017/S0033291715002627

**ETHICS STATEMENT**

This study was carried out in accordance with the recommendations of Swiss Ethics Committees on research involving humans with written informed consent from all subjects. All subjects gave written informed consent in accordance with the Declaration of Helsinki. The protocol was approved by the local Ethics committee in Zurich.

**AUTHOR CONTRIBUTIONS**

NT-W, SW, and MF designed the present study ETRo. NT-W, MG, SM, MJ, MK, NS, MZ-L, SW, and MF contributed to the development of the treatment manual and the smartphone application Robin for the intervention group. NT-W, MG, SM, and MF are collecting the data. AR is the data analyst for the project and undertook the statistical analysis. WR and SW designed the study of ZInEP “The Zurich Early Recognition Program” for the control group. NT-W, MG, SM, and MF collected the data for the control group. All authors have contributed to and have approved the final manuscript.
21. Masillo A, Valmaggia LR, Saba R, Brandizzi M, Lindau JF, Sofianelli A, et al. Interpersonal sensitivity and functioning impairment in youth at ultra-high risk for psychosis. *Eur Child Adolesc Psychiatry* (2016) 25(1):7–16. doi: 10.1007/s00787-015-0692-6

22. Metzler S, Dvořsky D, Wyss C, Müller M, Traber-Walker N, Walitza S, et al. Neurocognitive profiles in help-seeking individuals: comparison of risk for psychosis and bipolar disorder criteria. *Psychol Med* (2014) 44(16):3543–55. doi: 10.1017/S0033291714001007

23. Velthorst E, Zinberg J, Addington J, Cadenhead KS, Cannon TD, Carrión RE, et al. Potentially important periods of change in the development of social and role functioning in youth at clinical high risk for psychosis. *Dev Psychopathol* (2018) 30(1):39–47. doi: 10.1017/S0954579417000451

24. Robustelli BL, Newberry RE, Whisman MA, Mittal VA. Social relationships in young adults at ultra high risk for psychosis. *Psychiatry Res* (2017) 247:345–51. doi: 10.1016/j.psychres.2016.12.008

25. Cotter J, Yung AR, Carney R, Drake R. Metacognitive beliefs in the at-risk mental state: a systematic review and meta-analysis. *Behav Res Ther* (2017) 90:25–31. doi: 10.1016/j.brat.2016.12.004

26. Schmidt SJ, Grunert VM, Schimmelmann BG, Schultz-Lutter F, Michel C. Differences in coping, self-efficacy, and external control beliefs between patients at-risk for psychosis and patients with first-episode psychosis. *Psychiatry Res* (2014) 219(1):95–102. doi: 10.1016/j.psychres.2014.04.045

27. Sellers R, Gavenga I, Wells A, Morrison AP. The role of unhelpful metacognitive beliefs in psychotic relationships with positive symptoms and negative affect. *Psychiatry Res* (2016) 246:401–6. doi: 10.1016/j.psychres.2016.10.029

28. Lim J, Rekhi G, Rapisarda A, Lam M, Kraus M, Keefe RSE, et al. Impact of psychiatric comorbidity in individuals at ultra high risk of psychosis—findings from the Longitudinal Youth at Risk Study (LYRKS). *Schizophr Res* (2015) 164(1–3):8–14. doi: 10.1016/j.schres.2015.03.007

29. McAuland L, Buchy L, Cadenhead KS, Cannon TD, Cornblatt BA, Heinsen R, et al. Anxiety in youth at clinical high risk for psychosis. *Early Interv Psychiatry* (2017) 11(6):480–7. doi: 10.1111/eip.12274

30. Rutigliano G, Valmaggia L, Landi F, Frascarelli M, Cappucciati M, Sear V, et al. Persistence or recurrence of non-psychotic comorbid mental disorders associated with 6-year poor functional outcomes in patients at ultra high risk for psychosis. *J Affect Disord* (2016) 203:101–10. doi: 10.1016/j.jad.2016.05.053

31. Mallà A, de Bonneville M, Shah J, Jordan G, Pruessner M, Faridi K, et al. Outcome in patients converting to psychosis following a treated clinical high risk state. *Early Interv Psychiatry* (2018) 12(4):715–9. doi: 10.1111/eip.12129

32. Armando M, Pontillo M, Vicari S. Psychosocial interventions for very early psychosis: a systematic review and meta-analysis. *Journal of the American Academy of Child & Adolescent Psychiatry* (2019) 58(4):340–3. doi: 10.1093/jaac/887-012-0242-x

33. Baker K, Howell C, Findling RL. Current treatment trends of psychosis in youth with schizophrenia. *Psychiatry Res* (2016) 246:401–6. doi: 10.1016/j.psychres.2016.10.029

34. Hutton P, Taylor PJ. Cognitive behavioural therapy for psychosis prevention: a systematic review and meta-analysis. *Psychol Med* (2014) 44(3):449–68. doi: 10.1017/S0033291713000354

35. Pinquart M, Olesiek B, Teubert D. Efficacy of systemic therapy on adults with mental disorders: a meta-analysis. *Psychotherapy Res* (2016) 26(2):241–57. doi: 10.1080/03069880801926400

36. Schimmelmann BG. *Psychosen in der Adoleszenz: Entwicklungspsychopathologie, Früherkennung und Behandlung*. Stuttgart: Kohlhammer (2013).

37. Schimmelmann BG, Schmidt SJ, Carbon M, Correll CU. Treatment of adolescents with early-onset schizophrenia spectrum disorders: in search of a rational, evidence-informed approach. *Curr Opin Psychiatry* (2013) 26(2):219–30. doi: 10.1097/YCO.0b0133835dca2a

38. Traber-Walker et al. Persistence or recurrence of non-psychotic comorbid mental disorders associated with 6-year poor functional outcomes in patients at ultra high risk for psychosis. *J Affect Disord* (2016) 203:101–10. doi: 10.1016/j.jad.2016.05.053
for a fully mobile randomized controlled trial. Front Public Health (2017) 5:249. doi: 10.3389/fpubh.2017.00249
61. Reid SC, Kauer SD, Heaps HC, Brooke AHD, Khor AS, Sanci IA, et al. A mobile phone application for the assessment and management of youth mental health problems in primary care: health service outcomes from a randomised controlled trial of mobiletype. BMC Fam Pract (2013) 14(1):84. doi: 10.1186/1471-2296-14-84
62. Granholm E, Ben-Zeev D, Link PC, Bradshaw KR, Holden JL. Mobile assessment and treatment for schizophrenia (MATs): a pilot trial of an interactive text-messaging intervention for medication adherence, socialization, and audit hallucinations. Schizophr Bull (2012) 38(3):414–25. doi: 10.1093/schbul/sbr155
63. Kauppi K, Kannisto KA, Hätönen H, Anttila M, Löytyniemi E, Adams CE, et al. Mobile phone text message reminders: measuring preferences of people with antipsychotic medication. Schizophr Res (2015) 168(1–2):514–22. doi: 10.1016/j.schres.2015.07.044
64. Ben-Zeev D, Brian R, Wang R, Wang W, Campbell AT, Aung MSH, et al. CrossCheck: integrating self-report, behavioral sensing, and smartphone use to identify digital indicators of psychotic relapse. Psychiatr Rehabil J (2017) 40(1):266–75. doi: 10.1037/prp0000243
65. Bucci S, Barrowclough C, Ainsworth J, Morris R, Berry K, et al. Actisist: proof-of-concept trial of a theory-driven digital intervention for psychosis. Schizophr Bull (2018) 44(5):1070–80. doi: 10.1093/schbul/sby032
66. Pesola W, Isabell G, Ariane K, Yoram C, Graham H B, Zielasek J, et al. European Psychiatric Association (EPA) guidance on the quality of eMental health interventions in the treatment of psychotic disorders. Eur Arch Psychiatry Clin Neurosci (2016) 266(2):125–37. doi: 10.1007/s00406-016-0677-6
67. Schlosser DA, Campbellle TR, Truong B, Etter K, Vergani S, Komaiko K, et al. Efficacy of PRIME, a mobile app intervention designed to improve motivation in young people with schizophrenia. Schizophr Bull (2018) 44(5):1010–20. doi: 10.1093/schbul/sby078
68. Toros J, Firth J, Mueller N, Omnła JP, Baker JT. Methodology and reporting of mobile health and smartphone application studies for schizophrenia. Harv Rev Psychiatry (2017) 25(3):146–54. doi: 10.1097/HRP.0000000000000133
69. Whittaker R, Merry S, Stasiak K, McDowell H, Doherty I, Shepherd M, et al. MEMO—a mobile phone depression prevention intervention for adolescents: development process and postprogram findings on acceptability from a randomized controlled trial. J Med Internet Res (2012) 14(1):e13. doi: 10.2196/jmir.1857
70. Fusar-Poli P, Cappucciati M, Borgwardt S, Woods SW, Addington J, Nelson B, et al. Heterogeneity of psychosis risk within individuals at clinical high risk: a meta-analytical stratification. Schizophr Bull (2003) 29(4):703–15. doi: 10.1093/schbul/371
71. Schultze-Lutter F, Koch E. Schizophrenia Proneness Instrument, Child and Youth Version (SPI-CY). Rome: Fioriti (2010). Retrieved from https://www.fioritiditore.com/prodotto/schizophrenia-proneness-instrument-child-and-youth-spi-cy-extended-english-version/
72. Miller TJ, McGlashan TH, Rosen JL, Cadenhead K, Ventura J, McFarlane W, et al. Prodomal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull (2003) 29(4):703–15. doi: 10.1093/oxfordjournals.schbul.a007040
73. Theodorou A, Heekeren K, Dvorsky D, Metzler S, Frasnini M, Haker H, et al. Early recognition of high risk of bipolar disorder and psychosis: an overview of the ZInEP “Early Recognition” Study. Front Public Health (2014) 2:166. doi: 10.3389/fpubh.2014.00166
74. Kuhl J, Kassin M. Persönlichkeits-Stil- und-Störungs-Inventar (PSSI). Göttingen: Hogrefe (2009).
75. Petermann F, Petermann U. Hamburg-Wechsler-Intelligenztest für Kinder IV (HAWIK-IV). Bern: Huber (2007).
76. Jacobs C, Petermann F. Wechsler Intelligenztest für Erwachsene (WIE). Z. Psychiatr Psychother Psychother (2007) 35(5):205–8. doi: 10.1024/1661–4747.55.3.205
77. Sheehan DV, Lecrubier Y, Sheenan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry (1998) 59:22–33. doi: 10.1016/0022-0197(98)90239-9
78. Hamilton MC. Hamilton Depression Scale (HDS) with Melancholia Scale (MES). Acta Psychiatr Scand (1986) 73:23–8. doi: 10.1111/j.1600-0447.1986.tb10903.x
79. Hall RW. Global Assessment of Functioning: a modified scale. Psychosomatics (1995) 36(3):267–75. doi: 10.1016/S0033-3182(95)71666-8
80. Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioi R. Development, reliability and acceptability of a new version of the DSM-IV Social Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand (2000) 101(4):323–9. doi: 10.1034/j.1600-0447.2000.101004323.x
81. Cornblatt BA, Author AM, Niendam T, Smith CW, Zanberg J, Bearden CE, et al. Preliminary findings for two new measures of social and role functioning in the prodromal phase of schizophrenia. Schizophr Bull (2007) 33(3):688–702. doi: 10.1093/schbul/sbm029
82. Priebe S, Huxley P, Knight S, Evans S. Application and results of the Manchester Short Assessment of Quality of Life (MANSA). Int J Soc Psychiatry (1999) 45(1):7–12. doi: 10.1177/00207640990450010102
83. Schwarzer R, Jerusalem M. Generalized self-efficacy scale. Measures in health psychology: a user's portfolio. Causal and control beliefs (1995) 1(1):35–7.
84. Mattjeat F, Frenschmidt H. Fragebögen zur Beurteilung der Behandlung: FBB. Hogrefe Verlag für Psychologie (1998).
85. Wessels H, Wagner M, Kruh K, Berning J, Pützelf V, Janssen B, et al. Predictors of treatment response to psychological interventions in people at clinical high risk of first-episode psychosis. Early Interv Psychiatry (2017) 13(1):120–7. doi: 10.1111/eip.12460
86. McFarlane WR, Levin B, Travis L, Lucas FL, Lynch S, Verdi M, et al. Clinical and functional outcomes after 2 years in the early detection and intervention for the prevention of psychosis multisite effectiveness trial. Schizophr Bull (2015) 41(3):30–43. doi: 10.1093/schbul/bsu108
87. Nelson B, Yuen HP, Wood SJ, Lin A, Spilotocopoulos D, Bruxner A, et al. Long-term follow-up of a group at ultra high risk ("Prodromat") for psychosis the PACE 400 study. JAMA Psychiatry (2013) 70(8):793–802. doi: 10.1001/jamapsychiatry.2013.1270
88. Schimmelmann BG, Michl C, Martinez-Irgartinger A, Linder C, Schultze-Lutter F. Age matters in the prevalence and clinical significance of ultra-high-risk for psychosis symptoms and criteria in the general population: findings from the BEAR and BEARS-kid studies. World Psychiatry (2015) 14(2):189–97. doi: 10.1002/wps.20216
89. Davies C, Cipriani A, Ioannidis JPA, Radua J, Stahl D, Prozenzani U, et al. Lack of evidence to favor specific preventive interventions in psychosis: a network meta-analysis. World Psychiatry (2018) 17(2):196–209. doi: 10.1002/wps.20526

Conflict of Interest Statement: SW has received in the last 5 years royalties from Thieme, Hogrefe, Kohlhammer, Springer, and Beltz. Her work was supported in the last 5 years by the Swiss National Science Foundation (SNF), diff. EU FP7s, HSM Hochspezialisierte Medizin of the Kanton Zürich, Switzerland, Bfarm Germany, ZfinEP, Hartmann Müller Stiftung, Olga Mayenfisch, and Gertrud Thalmann Fonds. Outside professional activities and interests are declared under the link of the University of Zurich, www.uzh.ch/prof/sld/interessenbindungen/client/web/.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Traber-Walker, Gerstenberg, Metzler, Joris, Karr, Studer, Zulauf, Logoz, Roth, Rüssler, Waltiza and Frasnini. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.